Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | VHL | P40337 | 1/20 | 0.49 |
| ▸ | ELOC | Q15369 | 1/20 | 0.49 |
| ▸ | ELOB | Q15370 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567875 | 1.00 | KDM4E (0.55) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL567153 | 1.00 | KDM4E (0.55) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL11492156 | 0.87 | KDM4E (0.55) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL11492158 | 0.87 | KDM4E (0.55) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL566861 | 0.86 | KDM4E (0.54) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL16138620 | 0.86 | KDM4E (0.54) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL10060190 | 0.86 | KDM4E (0.54) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL566863 | 0.86 | KDM4E (0.54) | KDM4EMAOBVHLELOCELOB | |
| SCHEMBL567075 | 0.83 | EPHX2 (0.44) | KDM4EMAOBMAPTKMT2AMEN1 | |
| SCHEMBL566166 | 0.83 | AURKA (0.44) | KDM4EMAOBMAPTMIFL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423213-B1 | PREPARATION AND USE OF NOVEL ANTIBIOTIC, ANTICANCER COMPOUNDS AND DERIVATIVES THEREOF | YANG GENGLIANG (CN) | 2014-01-08 | — | — | EP | claimed |
| EP-2423213-A1 | PREPARATION AND USE OF NOVEL ANTIBIOTIC, ANTICANCER COMPOUNDS AND DERIVATIVES THEREOF | Yang, Gengliang (CN) | 2012-02-29 | — | — | EP | claimed |
| US-20120035206-A1 | PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG, Gengliang (CN) | 2012-02-09 | — | — | US | claimed |
| US-20140296285-A1 | PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG GENGLIANG (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296285-A1 | PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG GENGLIANG (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296285-A1 | PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG GENGLIANG (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2423213-B1 | PREPARATION AND USE OF NOVEL ANTIBIOTIC, ANTICANCER COMPOUNDS AND DERIVATIVES THEREOF | YANG GENGLIANG (CN) | 2014-01-08 | — | — | EP | disclosed |
| US-20120035206-A1 | PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG, Gengliang (CN) | 2012-02-09 | — | — | US | disclosed |
| US-20120035206-A1 | PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG, Gengliang (CN) | 2012-02-09 | — | — | US | disclosed |
| US-20120035206-A1 | PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | YANG, Gengliang (CN) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035206-A1 | PREPARATION AND APPLICATION OF NOVEL ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | MRPL21, NRDC, SOST | KDM4E 3551/4885MAOB 3447/4885VHL 1157/4885 |
| US-20140296285-A1 | PREPARATION AND APPLICATION OF THE NEW ANTIBACTERIAL AND ANTICANCER COMPOUNDS AND THEIR DERIVATIVES | MRPL21, MCL1, MYC | KDM4E 4116/4885MAOB 1058/4885VHL 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.